ArticleEuropean journal of haematology2020

c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma.

Alessandra Di Bacco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.